Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx Inc., on June 17, 2014 announced that the proof-of-concept pre-clinical studies were successful. Novogen and its joint venture company CanTx Inc. also gave confirmation of the potency of Intra-Peritoneal Trx-1, their experimental drug. Novogen Limited (ADR) (NASDAQ:NVGN) stock performance was -1.75% in last session and finished the day at $3.37. Traded volume was 19,720.00million shares in the last session … Continue reading New Lows: Novogen (NASDAQ:NVGN), Zafgen Inc (NASDAQ:ZFGN), Lpath (NASDAQ:LPTN), Ambit Biosciences (NASDAQ:AMBI)